Skip to end of metadata
Go to start of metadata
Labels
  • None
Page: CALGB 90601 A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients with Advanced Transitional Cell Carcinoma Page: GWU - A Phase 2 Study Evaluating the Efficacy of Docetaxel in Combination With Ramucirumab or IMC-18F1 or Without Investigational Therapy as Second-line Therapy in Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder Page: JHMI - CALGB90601 - A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients With Advanced Transitional Cell Carcinoma Page: JHMI ECALGB90601 - A Randomized double-blinded Phase III study comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin and placebo in patients with advanced Transitional Cell Carcinoma Page: JHMI J1154 Phase 2 Study Evaluating the Safety and Efficacy of Docetaxel in Combination with Ramucirumab or IMC18F1 or Without Investigational Therapy as Second line Therapy in Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder Page: NCI 11-C-0130 A Phase II Study of TRC105 in Adults With Advanced or Metastatic Urothelial Carcinoma Page: NCI 11-C-0140 A Phase I Study of Gemcitabine, Carboplatin and Lenalidomide (GCL) for Treatment of Patients With Advanced or Metastatic Urothelial Carcinoma (UC) and Other Solid Tumors Page: NCI 11-C-xxx Multi-Center Phase Ib,II Trial of Gemcitabine, Cisplatin, Plus Lenalidomide as First-line Therapy for Patients With Metastatic Urothelial Carcinoma Page: NCT01437488 Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy Page: NCT01688999 A Phase II Study of Cabozantinib (XL184) in Patients With Advanced Metastatic Urothelial Carcinoma Page: UMD - A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients With Advanced Transitional Cell Carcinoma Page: UMD - Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer